Increased Heme Levels in the Heart Lead to Exacerbated Ischemic Injury
暂无分享,去创建一个
Arineh Khechaduri | S. N. Naga Prasad | H. Ardehali | Rongxue Wu | Tatsuya Sato | Hsiang-Chun Chang | Meng Shang | K. Sawicki | C. Kamide | Ting Liu | R. Wu | K. T. Sawicki
[1] Y. Lopatin. Metabolic Therapy in Heart Failure. , 2015, Cardiac failure review.
[2] H. Ardehali,et al. Role of Heme in Cardiovascular Physiology and Disease , 2015, Journal of the American Heart Association.
[3] P. Ponikowski,et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† , 2014, European heart journal.
[4] M. Gheorghiade,et al. Molecular and Cellular Basis of Viable Dysfunctional Myocardium , 2014, Circulation. Heart failure.
[5] Steven P Jones,et al. Metabolomic Analysis of Pressure-Overloaded and Infarcted Mouse Hearts , 2014, Circulation. Heart failure.
[6] T. Poulos. Heme enzyme structure and function. , 2014, Chemical reviews.
[7] R. Mutharasan,et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. , 2014, The Journal of clinical investigation.
[8] Arineh Khechaduri,et al. Heme levels are increased in human failing hearts. , 2013, Journal of the American College of Cardiology.
[9] M. Gheorghiade,et al. Mitochondria as a therapeutic target in heart failure. , 2013, Journal of the American College of Cardiology.
[10] M. Laakso,et al. Hexokinase II knockdown results in exaggerated cardiac hypertrophy via increased ROS production , 2012, EMBO molecular medicine.
[11] R. Mutharasan,et al. Disruption of ATP-binding cassette B8 in mice leads to cardiomyopathy through a decrease in mitochondrial iron export , 2012, Proceedings of the National Academy of Sciences.
[12] Michael A. Burke,et al. Targeting myocardial substrate metabolism in heart failure: potential for new therapies , 2012, European journal of heart failure.
[13] K. Nakashima,et al. [The Rotterdam study]. , 2011, Nihon rinsho. Japanese journal of clinical medicine.
[14] R. Payne,et al. The Heart in Friedreich's Ataxia: Basic Findings and Clinical Implications. , 2011, Progress in pediatric cardiology.
[15] Anwara . Khan,et al. Control of intracellular heme levels: heme transporters and heme oxygenases. , 2011, Biochimica et biophysica acta.
[16] R. Bolli,et al. Cardioprotective and Antiapoptotic Effects of Heme Oxygenase-1 in the Failing Heart , 2010, Circulation.
[17] P. Ponikowski,et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.
[18] M. Tsironi,et al. Assessment and Treatment of Cardiac Iron Overload in Thalassemia , 2009, Hemoglobin.
[19] J. Barton,et al. Multi-Organ Iron Overload in an African-American Man with ALAS2 R452S and SLC40A1 R561G , 2008, Acta Haematologica.
[20] L. Wojnar,et al. Detection of mitochondrial dysfunction by EPR technique in mouse model of dilated cardiomyopathy. , 2008, Free radical biology & medicine.
[21] Y. Kohgo,et al. Body iron metabolism and pathophysiology of iron overload , 2008, International journal of hematology.
[22] J. Abkowitz,et al. A Heme Export Protein Is Required for Red Blood Cell Differentiation and Iron Homeostasis , 2008, Science.
[23] P. Ponikowski,et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. , 2008, Journal of the American College of Cardiology.
[24] P. Duarte,et al. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. , 2007, Journal of the American College of Cardiology.
[25] Kiriko Kaneko,et al. Heme as a magnificent molecule with multiple missions: heme determines its own fate and governs cellular homeostasis. , 2007, The Tohoku journal of experimental medicine.
[26] L. Opie,et al. Metabolic mechanisms in heart failure. , 2007, Circulation.
[27] L. Papadopoulou,et al. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects. , 2006, Pharmacology & therapeutics.
[28] Li Zhang,et al. Heme: a versatile signaling molecule controlling the activities of diverse regulators ranging from transcription factors to MAP kinases , 2006, Cell Research.
[29] Sanjay Kumar,et al. Free heme toxicity and its detoxification systems in human. , 2005, Toxicology letters.
[30] Albert Hofman,et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. , 2004, European heart journal.
[31] N. Wijayanti,et al. Biology of heme in health and disease. , 2004, Current medicinal chemistry.
[32] S. Laradi,et al. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. , 2003, Clinica chimica acta; international journal of clinical chemistry.
[33] G. Francis,et al. Heart failure therapy at a crossroad: are there limits to the neurohormonal model? , 2003, Journal of the American College of Cardiology.
[34] P. Aisen,et al. Chemistry and biology of eukaryotic iron metabolism. , 2001, The international journal of biochemistry & cell biology.
[35] J. Alam,et al. Hmox-1 Constitutes an Adaptive Response to Effect Antioxidant Cardioprotection: A Study With Transgenic Mice Heterozygous for Targeted Disruption of the Heme Oxygenase-1 Gene , 2001, Circulation.
[36] P. Sarathchandra,et al. Heme oxygenase-1-derived bilirubin ameliorates postischemic myocardial dysfunction. , 2000, American journal of physiology. Heart and circulatory physiology.
[37] S. Ryter,et al. The heme synthesis and degradation pathways: role in oxidant sensitivity. Heme oxygenase has both pro- and antioxidant properties. , 2000, Free radical biology & medicine.
[38] T. Sadlon,et al. Regulation of erythroid 5-aminolevulinate synthase expression during erythropoiesis. , 1999, The international journal of biochemistry & cell biology.
[39] D. Bagchi,et al. Oxidative mechanisms in the toxicity of metal ions. , 1995, Free radical biology & medicine.
[40] J. Kushner,et al. Heme regulation of HeLa cell transferrin receptor number. , 1984, The Journal of biological chemistry.
[41] F. Takaku,et al. Aminolevulinic acid synthetase activity in erythroblasts of patients with primary sideroblastic anemia. , 1973, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society.
[42] E. Beutler,et al. Severe iron overload with a novel aminolevulinate synthase mutation and hepatitis C infection. A case report. , 2009, Blood cells, molecules & diseases.
[43] A. Koeppen,et al. Iron and iron-responsive proteins in the cardiomyopathy of Friedreich’s ataxia , 2008, The Cerebellum.
[44] M. Gassmann,et al. Hypoxic up-regulation of erythroid 5-aminolevulinate synthase. , 2003, Blood.
[45] P. Ponka. Tissue-specific regulation of iron metabolism and heme synthesis: distinct control mechanisms in erythroid cells. , 1997, Blood.
[46] R. Meneghini. Iron homeostasis, oxidative stress, and DNA damage. , 1997, Free radical biology & medicine.
[47] F. Takaku,et al. -Aminolevulinic acid synthetase activity of human bone marrow erythroid cells in various hematological disorders. , 1972, The Tohoku journal of experimental medicine.
[48] W. Tourtellotte,et al. JCB: ARTICLE Transcriptional regulation of myotube fate specification and intrafusal muscle fiber morphogenesis , 2022 .